

AMENDMENTS

1. (previously presented) A compound 12 to 50 nucleobases in length targeted to a region comprising nucleotide 901 to 950 of the nucleic acid molecule encoding diacylglycerol acyltransferase 2 in SEQ ID NO: 4, wherein said compound is at least 80% complementary to said nucleic acid molecule encoding diacylglycerol acyltransferase 2, and wherein said compound comprises at least an 8 nucleobase portion of SEQ ID NO: 35, 36, 37 or 38.
2. (canceled)
3. (previously presented) The compound of claim 1, wherein said compound is 15 to 30 nucleobases in length.
4. (original) The compound of claim 1 comprising an oligonucleotide.
5. (previously presented) The compound of claim 4 comprising an antisense oligonucleotide.
6. (original) The compound of claim 4 comprising a DNA oligonucleotide.
7. (original) The compound of claim 4 comprising a RNA oligonucleotide.
8. (original) The compound of claim 4 comprising a chimeric oligonucleotide.
9. (original) The compound of claim 4 wherein at least a portion of said compound hybridizes with RNA to form an oligonucleotide-RNA duplex.
10. (canceled).
11. (original) The compound of claim 1 having at least 90% complementarity with said nucleic acid molecule encoding diacylglycerol acyltransferase 2.
12. (previously presented) The compound of claim 1 having at least 95% complementarity with said nucleic acid molecule encoding diacylglycerol acyltransferase 2.
13. (previously presented) The compound of claim 1 having 100% complementarity with said nucleic acid molecule encoding diacylglycerol acyltransferase 2.

14. (previously presented) The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
15. (original) The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.
16. (original) The compound of claim 1 having at least one phosphorothioate internucleoside linkage.
17. (original) The compound of claim 1 having at least one 5-methylcytosine.
- 18.-21. (canceled)
22. (original) A kit or assay device comprising the compound of claim 1.
- 23.-43. (canceled)
44. (original) The compound of claim 1, wherein said compound comprises an antisense nucleic acid molecule that is specifically hybridizable with a coding region of the diacylglycerol acyltransferase 2 (SEQ ID NO: 4).
45. - 57. (canceled)
58. (previously presented) The compound of claim 1, wherein said compound is 20 nucleobases in length.
59. (previously presented) The compound of claim 13 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
60. (previously presented) A compound 20 nucleobases in length targeted to a nucleic acid molecule encoding diacylglycerol acyltransferase 2 (SEQ ID NO: 4), wherein said compound has the nucleobase sequence of SEQ ID NO: 35.
61. (previously presented) The compound of claim 60, wherein said compound is an antisense oligonucleotide comprising:
- a gap segment consisting of linked deoxynucleosides;
 - a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

62. (previously presented) The compound of claim 61, wherein the antisense oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.

63. (previously presented) The compound of claim 62, wherein each cytosine is a 5-methylcytosine.

64. (new) The compound of claim 62, wherein the deoxynucleosides are 2'-deoxynucleosides.

65. (new) The compound of claim 63, wherein the deoxynucleosides are 2'-deoxynucleosides.